Eton Pharmaceuticals Q4 Earnings Call Highlights
Eton Pharmaceuticals (NASDAQ:ETON) reported fourth quarter 2025 product revenue of $21.3 million, an 83% increase from $11.6 million in the prior-year period, as the company highlighted continued growth in its base business, contributions from recent product relaunches, and the early rollout of its...